Niagen Bioscience (FRA:OCD1) Moat Score: 4/10 (As of Sep. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OCD1 Niagen Bioscience Inc FRA:OCD1
68 GF Score
Price €2.38
GF Value €3.77
! 2 Warning Signs
View Full Analysis

What is Niagen Bioscience Moat Score?

Niagen Bioscience FRA:OCD1 +10.19% 68 Moat Score is 4 as of Sep. 18, 2026. GuruFocus rates FRA:OCD1 with a GF Score™ of 68/100 and a GF Value™ of €3.77. The stock has 2 warning signs investors should review. Among 2,051 Consumer Packaged Goods companies, Niagen Bioscience ranks better than 93.52% on this metric.

Niagen Bioscience has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Niagen Bioscience has Narrow Moat: Niagen Bioscience Inc has a discernible but modest moat due to its niche market presence and some valuable intellectual property. However, it lacks strong brand strength, significant customer switching costs, and durable cost advantages, limiting its competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Niagen Bioscience might have Narrow Moat - Discernible but modest moat.

Niagen Bioscience  (FRA:OCD1) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Niagen Bioscience Moat Score Related Terms

FRA:OCD1 vs CAMP, ALEC, ELDN: Moat Score Comparison

For the Packaged Foods subindustry, Niagen Bioscience's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Niagen Bioscience Moat Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's Moat Score distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Moat Score falls into.


FRA:OCD1
68GF Score
Niagen Bioscience Inc FRA:OCD1
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Niagen Bioscience (FRA:OCD1) has a Moat Score of 4 as of Sep. 18, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Niagen Bioscience ranks #133 out of 2051 companies in the Consumer Packaged Goods industry, placing it in the top 6.5%.
Is Niagen Bioscience's Moat Score too high?
Niagen Bioscience's current Moat Score is 4. Based on the distribution chart, Niagen Bioscience ranks #133 out of 2051 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Niagen Bioscience has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's Moat Score compare to CAMP and ALEC?
According to the Consumer Packaged Goods industry distribution chart, Niagen Bioscience ranks #133 out of 2051 companies for Moat Score. This places Niagen Bioscience in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Consumer Packaged Goods company?
A good Moat Score depends on the Consumer Packaged Goods industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Niagen Bioscience's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Niagen Bioscience (FRA:OCD1) has a current Moat Score of 4. The stock's GF Value™ is €3.77, compared to a current price of €2.38 — trading 36.9% below its estimated fair value. The current Moat Score is 4. Niagen Bioscience's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current Moat Score is 4 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.38 is trading 36.9% below its estimated GF Value™ of €3.77.

Key valuation signals for FRA:OCD1:

  • Moat Score: 4
  • GF Value™: €3.77 vs. price of €2.38 (36.9% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Niagen Bioscience Business Description

Other Exchanges NAGE:USAOCD1:Germany
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score

Get the complete analysis for FRA:OCD1

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.38
Price
€3.77
GF Value